*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.
GEN’s editorial staff interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.
Scientists at the Institute of Systems Biology report that research has shown that circulating miRNAs might serve as biomarkers for liver damage caused by drugs such as acetaminophen. During this week's podcast Dr. David Galas talks about why miRNAs have become such important life science research tools and explains what his team was able to demonstrate in an miRNA experiment with mice. He discusses the design of the study and how they achieved the results published in PNAS.
Dr. Galas presents his thoughts on the potential advantages of using circulating miRNAs for assessing drug-induced liver damage and on the transferability of animal research results to human studies.
David Galas, PhD, is senior vice president of Strategic Partnerships at the Institute for Systems Biology where he conducts his research and leads multi-investigator projects. Formerly he served as: Chief science officer for Life Sciences of the Battelle Memorial Institute; Co-founder, chancellor, chief scientific officer and Norris Professor of Applied Life Science at the Keck Graduate Institute of Applied Life Sciences (KGI); President and chief scientific officer of Seattle-based Chiroscience R&D; Director for Health and Environmental Research at the U.S. Department of Energy's Office of Science, where he headed the DOE's Human Genome Project from 1990 to 1993 while on leave from the University of Southern California; and Professor of Molecular Biology at USC, on the faculty for twelve years, and chairman for five years. He has served on many federal, university and corporate boards and is a lifetime National Associate of the National Academy of Sciences.